Tag:
Tekmira
Latest Headlines
Latest Headlines
FDA to rule soon on Tekmira-created nanoparticle chemo drug
May 13 is the do-or-die date for Marqibo, a nanoparticle-delivered injectable cancer drug conceived by Canada's Tekmira Pharamceuticals ( $TKMR ).
Tekmira seeks court's rejection of Alnylam drug delivery patent suit
Tekmira Pharmaceuticals ($TKMR) fired back at Alnylam Pharmaceuticals ($ALNY) in federal court this week, with an attempt to get rid of the Massachusetts company's patent lawsuit over siRNA and lipid nanoparticle drug delivery technology.
Ensysce says carbon nanotubes delivered cancer drug
Ensysce Biosciences says early in vivo experiments using single-walled carbon nanotubes to deliver siRNA drugs to cancer tumors have been so promising, the company will proceed to human clinical
UPDATED: Alnylam throws legal punch in patent fight with RNAi tech partner Tekmira
This is growing nastier. Alnylam Pharmaceuticals ( $ALNY ) has fired the latest round—this time in federal court—in an ongoing patent feud with development partner Tekmira Pharmaceuticals (...
Alnylam, Tekmira separately tout amyloidosis RNAi treatment news
Alnylam Pharmaceuticals ( $ALNY ) says it generated promising Phase I trial results for an RNAi compound designed to treat a form of amyloidosis using lipid nanoparticle drug-delivery technology...
Arrowhead grabs RNAi delivery assets in Roche deal
Arrowhead Research ( $ARWR ) has parachuted into the bombarded field of RNAi therapeutics armed with Swiss drug giant Roche 's assets. As part of Pasadena, CA-based Arrowhead's acquisition of Roche's
Tekmira sues RNAi drug-delivery partner Alnylam
The pursuit to develop particles to deliver RNA-interference drugs has turned ugly. Tekmira Pharmaceuticals ( $TKMR ) said March 16 it had filed litigation against long-time partner Alnylam
Roche drops a bomb on the RNAi field
As FierceBiotech reported yesterday , Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany,
Tekmira to delay start of trial for TKM-ApoB
Tekmira Pharmaceuticals announced today that it has decided to delay the start of the next clinical trial of TKM-ApoB, which is being developed as a treatment for patients with high LDL cholesterol
DOD taps Tekmira for Ebola treatment
The U.S. Department of Defense has recruited a few good nanoparticles from Tekmira Pharmaceuticals to deliver RNAi therapeutics in the fight against the deadly Ebola virus. Tekmira, based in
